Ignite Creation Date:
2025-12-25 @ 12:34 AM
Ignite Modification Date:
2026-02-01 @ 12:10 PM
Study NCT ID:
NCT00493467
Status:
COMPLETED
Last Update Posted:
2022-09-15
First Post:
2007-06-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-06
Start Date Type:
None
Primary Completion Date:
2015-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-08-11
Completion Date Type:
ACTUAL
First Submit Date:
2007-06-27
First Submit QC Date:
None
Study First Post Date:
2007-06-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-04-20
Results First Submit QC Date:
None
Results First Post Date:
2020-09-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-30
Last Update Post Date:
2022-09-15
Last Update Post Date Type:
ACTUAL